<DOC>
	<DOCNO>NCT01147861</DOCNO>
	<brief_summary>The aim study verify whether significant decrease glucose level achieve HM74A agonist GSK256073 type 2 diabetic patient . Several dose level placebo evaluate three period crossover study two active dos one placebo dose per subject , order determine whether dose produce glucose lower target population . In addition , study investigate optimal dose regimen full manifestation metabolic effect GSK256073 compare day versus twice day regimen .</brief_summary>
	<brief_title>A Phase 1 Study Evaluate Effect GSK256073 , HM74A Receptor Agonist , Glucose NEFA Levels Type 2 Diabetics</brief_title>
	<detailed_description>This multi-center study enroll approximately 36 subject . The study consist three period two day dose . The study evaluate 5 potential dose regimen . Each subject receive randomize sequence treatment three period , placebo treatment one period two different active dose regimen two period . There 5 12 day outpatient washout treatment period . Subjects continue current treatment metformin throughout study . Subjects monitor blood glucose level daily via glucometer oupatient washout period . A follow-up visit occur 5 10 day last period study .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Subjects document ( less 6 month prior screen ) type 2 diabetes mellitus diagnosis : HbA1c level great 6.5 percent less equal 9.5 percent screening , On monotherapy metformin time screening , todal daily dose great equal 1000 mg time dosing , Fasting plasma glucose level less 270 mg/dl screen Male female 20 70 year age inclusive , time signing informed consent Waist circumference 102cm ( 40 inch ) men , 88cm ( 35 inch ) woman Fasting triglyceride 150 mg/dl 500 mg/dl , inclusive BMI within range 2237 kg/meter square , inclusive A subject eligible inclusion study follow criterion apply : Requiring insulin therapy use combination oral antidiabetic medication use monotherapy metformin within 3 month prior screen Past present disease ( type 2 diabetes mellitus ) opinion Investigator may affect outcome study . These disease include follow limited , cardiovascular disease , malignancy , hepatic disease , renal disease , hematological disease , neurological disease , gastrointestinal disease endocrine disease A positive prestudy Hepatitis B surface antigen , positive Hepatitis C HIV antibody result within 3 month screen Renal impairment define calculated GFR le 60 ml/min Any concurrent serious illness ( e.g. , severe COPD , history malignancy skin cancer within 5 year initial diagnosis evidence recurrence ) may interfere subject complete study Clinical laboratory value define per protocol ECG parameter define per protocol History gout and/or hyperuricemia/uric acid kidney stone treat drug hyperuricemia : allopurinol and/or probenecid Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) Use follow blood pressure medication medication renally excrete via OAT prohibit : Enalapril ( dose ) , Losartan ( dose ) , Captopril ( dose ) Pregnant female determine positive serum hCG test screen positive urine hCG test prior dose Lactating female</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>T2DM</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>GSK256073</keyword>
</DOC>